News Coverage 10.28.20 Share on Twitter Share on Facebook Share on LinkedIn Blood Test Could Predict the Best Type of Treatment for Metastatic Melanoma A new study finds that people with lower levels of tumor DNA in their blood stream may be better candidates for immune checkpoint inhibitors as a first treatment. Determining Treatment for Metastatic Melanoma A blood test or “liquid biopsy” can pick up bits of tumor DNA in your bloodstream. Lower levels of circulating tumor DNA could mean you’ll have a better response to immune checkpoint inhibitors for metastatic melanoma. Use of liquid biopsy is increasing across all phases of cancer screening, diagnosis and treatment. Related Announcement, Partner Highlight, Press Release PICI, Immunai to Build Landmark Cancer Dataset Announcement, Our Impact PICI at AACR 2025: Data, Direction, Impact Announcement, Press Release Dr. Ira Mellman Joins PICI as President of Research